Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
Review
Nature Reviews Microbiology 6, 529–540 (1 July 2008) | doi:10.1038/nrmicro1927
Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded
&
Abstract
Virotherapy is currently undergoing a renaissance, based on our improved understanding of virus biology and genetics and our better knowledge of many different types of cancer. Viruses can be reprogrammed into oncolytic vectors by combining three types of modification: targeting, arming and shielding. Targeting introduces multiple layers of cancer specificity and improves safety and efficacy; arming occurs through the expression of prodrug convertases and cytokines; and coating with polymers and the sequential usage of different envelopes or capsids provides shielding from the host immune response. Virus-based therapeutics are beginning to find their place in cancer clinical practice, in combination with chemotherapy and radiation.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
